ANALYTICAL FORMULATIONS

CERTIFICATE OF ANALYSIS

REPORT ID	VERIFICATION CODE	CLIENT	STATUS
AF-2026-516815	M6LN-VLZG	China Peptide Source	ACTIVE
PRODUCT	**BATCH / LOT**	**SAMPLE RECEIVED**	**ANALYSIS DATE**
Tesamorelin 5 mg + MGF 500 mcg + Ipamorelin 2.5 mg Blend (8 mg Total)	TMIP-35Z9	Jul 28, 2026	Jul 30, 2026

CORE ANALYTICAL PANEL

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Purity	RP-HPLC	99.29%	≥99.00%	Conforms
Multi-Analyte Assay	HPLC (Component Profile)	All declared components resolved	Declared component profile	Conforms
Net Content Quantity	Gravimetric	8.010 mg	8 mg Target	Conforms

BIOSAFETY & SCREENING

SAFETY TEST	METHOD	OBSERVED LEVEL	LIMIT	STATUS
Endotoxin Assay (LAL)	LAL	0.664 EU/mg	≤ 5.0 EU/mg	Pass
Heavy Metal Screen (ICP-MS)	ICP-MS	0.060 ppm	< 0.1 ppm	Pass

ADDITIONAL ANALYTICAL RESULTS

TEST PARAMETER	METHOD	RESULT	SPECIFICATION	STATUS
Component Ratio	HPLC (Component Area Ratio)	10:1:5 (Tesamorelin:MGF:Ipamorelin)	Declared ratio 10:1:5	Conforms
Appearance	Visual Inspection	White lyophilized cake	Product specification	Conforms
Water Content	Karl Fischer	0.40%	≤ 1.0%	Pass
Related Substances	RP-HPLC (Impurities)	< 0.10%	≤ 1.0%	Pass
Residual Solvents	Headspace GC	< 10 ppm	≤ 5000 ppm	Pass

METHOD & SAMPLE SUMMARY

PRIMARY METHOD	MATRIX	SAMPLE SIZE
RP-HPLC	Lyophilized Blend	8 mg
METHOD REFERENCE	**OVERALL DISPOSITION**	
AF-MULTI-QC-01	CONFORMS	

VERIFICATION

M6LN-VLZG

https://analyiticalformulations.com/verify/M6LN-VLZG

Lab ID: AFL-001 · FormuVerify™

Scan to verify certificate